Related Experiment Video
Updated: Feb 26, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
Ingrid Garajová1,2, Manuela Ferracin3, Elisa Porcellini4
1Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Sant'Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy. ingegarajova@gmail.com.
Abstract:
The onset and selection of resistant clones during cancer treatment with chemotherapy or targeted therapy is a major issue in the clinical management of metastatic colorectal cancer patients. It is possible that a more personalized treatment selection, using reliable response-to-therapy predictive biomarkers, could lead to an improvement in the success rate of the proposed therapies. Although the process of biomarker selection and validation could be a long one, requiring solid statistics, large cohorts and multicentric validations, non-coding RNAs (ncRNAs) and in particular microRNAs, proved to be extremely promising in this field. Here we summarize some of the main studies correlating specific ncRNAs with sensitivity/resistance to chemotherapy, anti-VEGF therapy, anti-EGFR therapy and immunotherapy in colorectal cancer (CRC).
Insights
Non-coding RNAs (ncRNAs), especially microRNAs, show promise as biomarkers for predicting treatment response in metastatic colorectal cancer (CRC). These biomarkers could personalize therapy, improving outcomes for patients undergoing chemotherapy or targeted treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Treatment resistance in metastatic colorectal cancer (CRC) is a significant clinical challenge.
- Personalized treatment strategies utilizing predictive biomarkers are needed to improve therapeutic success rates.
Purpose of the Study:
- To review current research on non-coding RNAs (ncRNAs) as predictive biomarkers for treatment response in colorectal cancer.
- To explore the potential of microRNAs in predicting sensitivity or resistance to various colorectal cancer therapies.
Main Methods:
- Literature review of studies correlating ncRNAs with treatment response in CRC.
- Analysis of data linking specific ncRNAs to chemotherapy, anti-VEGF, anti-EGFR, and immunotherapy outcomes.
Main Results:
- Non-coding RNAs, particularly microRNAs, are emerging as promising predictive biomarkers in CRC.
- Specific ncRNAs have been correlated with patient sensitivity and resistance to diverse therapeutic modalities.
Conclusions:
- ncRNAs represent a potential avenue for developing personalized treatment selection in colorectal cancer.
- Further validation of ncRNAs as biomarkers is crucial for clinical application in improving CRC patient management.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
